FZD10 is a G protein-coupled Wnt receptor that functions primarily in the canonical Wnt/β-catenin signaling pathway, leading to disheveled activation, GSK-3 inhibition, β-catenin nuclear accumulation, and transcriptional activation of Wnt target genes 1. Beyond canonical signaling, FZD10 also participates in non-canonical pathways involving PKC and calcium fluxes, with potential roles in tissue morphogenesis and polarity information transduction. FZD10 has significant disease relevance, particularly in cancer development and progression. In hepatocellular carcinoma, elevated FZD10 expression—regulated by METTL3-dependent N6-methyladenosine methylation—promotes liver cancer stem cell self-renewal and lenvatinib resistance through β-catenin/YAP1 activation 1. FZD10-containing exosomes sustain cancer cell proliferation across colorectal, gastric, hepatic, and cholangiocarcinoma cells, potentially mediating long-distance metastatization 2. FZD10 is highly expressed in synovial sarcoma tumors but absent in most normal tissues, making it an attractive therapeutic target 34. Clinically, FZD10 shows promise as both a prognostic biomarker and therapeutic target. Radioimmunotherapy with anti-FZD10 antibodies demonstrates feasibility in synovial sarcoma patients 4, while FDA-approved drugs targeting FZD10 show cytotoxicity against nasopharyngeal carcinoma cells 5. Additionally, FZD10+ cochlear glial cells exhibit neuronal differentiation potential enhanced by Wnt signaling 6, suggesting broader regenerative medicine applications.